Regulus Therapeutics Inc
Closed
0
Overview
Share price change
24h
Min
Max
Recommendations | Neutral |
|---|---|
12 Months Forecast | +4.17% upside |
Regulus Therapeutics Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Regulus Therapeutics Inc Forecast
Price Target
By TipRanks
4.17% upside
12 Months Forecast
Average 8.5 USD 4.17%
High 11 USD
Low 7 USD
Based on 5 Wall Street analysts offering 12 month price targets forRegulus Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Regulus Therapeutics Inc
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
